Severe Psoriasis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 66 pages report, published by Global Markets Direct

Keywords : Severe Psoriasis Therapeutic Products under Development, Key Players in Severe Psoriasis Therapeutics, Severe Psoriasis Pipeline Overview, Severe Psoriasis Pipeline, Severe Psoriasis Pipeline Assessment

Report ThumbnailSeptember-2013
Severe Psoriasis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Severe Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Severe Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Psoriasis. Severe Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Severe Psoriasis.
- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Severe Psoriasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Severe Psoriasis, H2 2013 8
  • Products under Development for Severe Psoriasis - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Route of Administration, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Molecule Type, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 27
  • List of Tables
  • Number of Products Under Development for Severe Psoriasis, H2 2013 8
  • Products under Development for Severe Psoriasis - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Johnson & Johnson, H2 2013 16
  • Boehringer Ingelheim GmbH, H2 2013 17
  • Amgen Inc., H2 2013 18
  • Eli Lilly and Company, H2 2013 19
  • Idera Pharmaceuticals, Inc., H2 2013 20
  • Almirall, S.A., H2 2013 21
  • Vascular Biogenics Ltd., H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Stage and Molecule Type, H2 2013 27
  • Severe Psoriasis Therapeutics - Drug Profile Updates 49
  • Severe Psoriasis Therapeutics - Dormant Products 61
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Severe Psoriasis Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Severe Psoriasis 8
  • Severe Psoriasis Therapeutics under Development by Companies 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Severe Psoriasis Therapeutics - Products under Development by Companies 15
  • Companies Involved in Severe Psoriasis Therapeutics Development 16
  • Johnson & Johnson 16
  • Boehringer Ingelheim GmbH 17
  • Amgen Inc. 18
  • Eli Lilly and Company 19
  • Idera Pharmaceuticals, Inc. 20
  • Almirall, S.A. 21
  • Vascular Biogenics Ltd. 22
  • Severe Psoriasis - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Drug Profiles 28
  • brodalumab - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • AMG-811 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • AMG-557 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • ixekizumab - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • ixekizumab - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • IMO-3100 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • VB-201 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • guselkumab - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • guselkumab - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • Apo-805-K1 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • BI-655066 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • IMO-8400 - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • LAS-41008 - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • cyclosporine liposomal - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • Severe Psoriasis Therapeutics - Drug Profile Updates 49
  • Severe Psoriasis Therapeutics - Dormant Products 61
  • Severe Psoriasis - Product Development Milestones 62
  • Featured News & Press Releases 62
  • Oct 15, 2012: Idera Pharma Completes Patient Enrollment In Phase II Trial Of IMO-3100 In Patients With Psoriasis 62
  • Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 63
  • Appendix 65
  • Methodology 65
  • Coverage 65
  • Secondary Research 65
  • Primary Research 65
  • Expert Panel Validation 65
  • Contact Us 66
  • Disclaimer 66

Please select a license type

Share

Related Products

Global Markets DirectSevere Psoriasis - Pipeline Review, H2 2013Product ThumbnailSevere Psoriasis - Pipeline Review, H2 2013, Industry ReportProduct #: 113314
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved